BioCentury
ARTICLE | Company News

NICE does not recommend Chiesi's Lamzede for alpha-mannosidosis

May 25, 2018 6:18 PM UTC

U.K.’s NICE recommended against the use of Lamzede velmanase alfa from Chiesi Farmaceutici S.p.A. (Parma, Italy) to treat alpha-mannosidosis, an ultra-Orphan disease that affects about 25 people in England.

The European Commission approved the recombinant form of human alpha mannosidase in April to treat non-neurological manifestations in patients with mild to moderate alpha-mannosidosis (see BioCentury, April 6)...

BCIQ Company Profiles

Chiesi Farmaceutici S.p.A.